Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7055081 | 0.84 | MEN1 (0.45) | KDM4ESMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL7052739 | 0.83 | F2 (0.48) | KDM4ESMN1; SMN2ALDH1A1HPGDKMT2A | |
| SCHEMBL7056158 | 0.83 | KMT2A (0.56) | KDM4ESMN1; SMN2ALDH1A1NPFFR1NPFFR2 | |
| SCHEMBL7051579 | 0.82 | ALDH1A1 (0.41) | KDM4ESMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL7060014 | 0.81 | F2 (0.46) | KDM4EALDH1A1HPGDKMT2AMAPT | |
| SCHEMBL7057628 | 0.81 | ALDH1A1 (0.67) | ALDH1A1NPFFR1NPFFR2LMNAKMT2A | |
| SCHEMBL7056248 | 0.80 | KMT2A (0.46) | KDM4ESMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL16984472 | 0.79 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1HPGDBACE1 | |
| SCHEMBL7055769 | 0.79 | POLB (0.51) | KDM4ESMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL7059022 | 0.79 | ALDH1A1 (0.47) | KDM4ESMN1; SMN2ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834542-B2 | LXR modulators | BRISTO-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| EP-2968275-A1 | LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2014144037-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026664-A1 | 2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO) -PYRAMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, SRC KINASE INHIBITORS | BAYER CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0131973-B1 | NEW AMIDINE DERIVATIVES OF 2-SUBSTITUTED 4-PHENILIMIDAZOLE | ISTITUTO DE ANGELI S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
| US-4649150-A | ANTISECRETORY AGENTS | ISTITUTO DE ANGELI, S.P.A. (IT) | 1987-03-10 | — | — | US | disclosed |
| EP-0131973-A1 | New amidine derivatives of 2-substituted 4-phenilimidazole | ISTITUTO DE ANGELI S.p.A. (IT) | 1985-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | KDM4E 4560/4885SMN1; SMN2 459/4885ALDH1A1 390/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | KDM4E 1568/4885SMN1; SMN2 1337/4885ALDH1A1 4570/4885 |
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | KDM4E 3265/4885SMN1; SMN2 4731/4885ALDH1A1 3047/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | KDM4E 3447/4885SMN1; SMN2 2329/4885ALDH1A1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.